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is a small chance per stem cell divi-
sion of a disaster of replication that
leads to a dysfunctional, but not
dead, stem cell. In this model, with
time these damaged stem cells accu-
mulate, and eventually with aging,
tissue regeneration is compromised
as a result of their reduced function.
If correct, this model has implications
for regenerative medicine-based
approaches for aging therapy: if cell
division itself is toxic to adult, tissue-
specific stem cells, from where will
we make new ones when we grow
old?
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Methods to isolate and characterize stem cell populations from the lung are emerging, making it
possible to begin to map out the pathways that are required for stem cell function in the adult
lung. A new study by Ventura et al. (2007) points to a requirement for MAPK14 (also known as
p38a) in regulation of lung stem or progenitor cell proliferation and differentiation.The lung is a complex solid tissue that
has eluded stem cell biologists for
many years. Lung injury modeling in
rodents has suggested that adult lung
stem or progenitor cells exist, yet there
has been a paucity of lineage relation-
ship analysis in the pulmonary system
and little demonstration that lung cells
exhibit stem cell properties (recently
reviewed by Rawlins and Hogan
[2006]). The limited number of molecu-
lar markers for lung cells and previous
work assigning stem/progenitor cell
function without detailed analyses of
self-renewal or differentiation are key
factors which have precluded an un-
derstanding of stem cell identity in
the lung and knowledge of the
pathways required for adult lung
homeostasis.We previously demonstrated that
cells termed bronchioalveolar stem
cells (BASCs) are capable of self-re-
newal and differentiation (Kim et al.,
2005). BASCs reside in the distal lung
and coexpress Scgb1a1 (aka CC10,
CCSP, or CCA), a marker of the bron-
chiolar epithelial cells (Clara cells),
and prosurfactant protein C (SP-C),
amarker of the type II alveolar epithelial
cells (AT2 cells). BASCs are isolated
prospectively from fresh lung homoge-
nates using the cell surface phenotype
Sca1+CD34+CD31CD45 and cul-
tured to self-renew or differentiate into
Clara cells, AT2 cells, and type I alveo-
lar cells (lung epithelial cells that per-
form gas exchange). The molecular
pathways that regulate BASC function
in vivo and in vitro remain to bedefined.Cell StemVentura and colleagues have now
reported the isolation of a putative
stem or progenitor cell population
from the adult lung and show that the
fate of these cells is altered by
MAPK14 deletion (Ventura et al.,
2007). Mice bearing a conditional null
allele of Mapk14 were mated to mice
with large subunit RNA polymerase
II-driven Cre-ERT2 mice (RERTnERT).
Despite Cre-mediated recombination
in diverse tissues after systemic
tamoxifen treatment, the most promi-
nent phenotype was a severe disrup-
tion of pulmonary morphology with
amarked increase in cycling lung cells,
more numerous SP-C+ cells, and a
decrease in E-cadherin-positive cells
that were collectively interpreted
as lung differentiation defects.Cell 1, July 2007 ª2007 Elsevier Inc. 11
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PreviewsFigure 1. Model for the Potential Functions of MAPK14/p38a in Lung Stem or
Progenitor Cells
(Top) In normal adult lung, Clara cells (red), BASCs (yellow), AT1 cells (blue), and AT2 cells (green)
are quiescent. p38a may inhibit the proliferation of BASCs via the indicated or other pathways.
(Middle) In the context of lung development or injured lung, p38a function may be required to
activate a pathway that drives differentiation of BASCs to produce alveolar cells including AT1
and AT2 cells. Bottom, p38a deficiency results in increased numbers of lung cells with a BASC
phenotype that expand beyond their normal location, suggesting that p38a-dependent pathways
regulate proliferation and differentiation.Interestingly, Clara cells appear to be
unaffected in p38a-deficient lung,
suggesting that p38a-independent
mechanisms regulate the bronchiolar
lineage. MAPK14 deficiency appeared
to phenocopy C/EBPa depletion in
adult mice (Basseres et al., 2006),
and at the molecular level, MAPK14-
deficient lung exhibited decreased
deregulation of transcription factors
involved in lung development as well
as other pathways (see Figure 1). Cou-
pling MAPK14 deficiency with activa-
tion of oncogenic K-rasG12V expres-
sion resulted in more numerous and
larger lung tumors than in Mapk14-
heterozygous;K-rasG12V lungs.
Ventura et al. (2007) developed sev-
eral new assays for lung cell function to
determine if lung stem or progenitor
cell dysfunction caused the lung phe-
notype. First, they devised a means to
disaggregate lung tissue without
enzymatic digestion and subsequently
used FACS analysis to quantify the
incidence of cells with the intracellular
markers CC10 and SP-C. CC10+
SP-C+ lung cells were increased in
MAPK14 mutant lungs and, interest-12 Cell Stem Cell 1, July 2007 ª2007 Elsingly, were found outside their normal
location at the ends of airways (Kim
et al., 2005). Culturing a mixture of
lung cells led to an SP-C+ CC10+
phenotype that produced SP-C+
CC10 or SP-C CC10+ cells after
changing the culture conditions, sug-
gesting differentiation occurred. Re-
markably, this response was not
observed in cultures from Mapk14
mutant lung cells, nor in those from
Mapk14-heterozygotes treated with
the p38a inhibitor SB203580. Treat-
ment with an EGFR inhibitor or C/
EBPa appeared to rescue the defects
inMapk14mutant cultures, further im-
plicating these pathways in MAPK14-
mediated lung cell regulation. A model
for the authors’ interpretation of the re-
sults related to lung stem cell biology is
shown (Figure 1).
Supporting a role for MAPK14 in
lung epithelial cell differentiation,
a companion paper (Hui et al., 2007)
showed that Mapk14-deficient mice
died from respiratory failure. Embry-
onic deletion of MAPK14 using
a Mapk14-floxed allele (Engel et al.,
2005) in combination with MORE-Creevier Inc.mice resulted in defective neonatal
lung differentiation coupled with ex-
tensive infiltration of hematopoietic
cells and abnormal vasculature. He-
matopoietic cell-specific MAPK14 de-
ficiency did not lead to lung defects,
suggesting that that MAPK14 has
a cell-intrinsic role in embryonic lung
epithelial cells. In contrast to adult
lung, mutant embryonic lung did not
exhibit increased proliferation, al-
though specific cell types were not
analyzed. Hui et al. (2007) also showed
using a liver-specific Cre that MAPK14
has antioncogenic activity in the liver
and provided evidence that the JNK-
c-Jun pathway downstream of p38a
plays a role in all of these contexts.
Together, these papers shed new
light on the functions of MAPK14
in vivo. This work expands on previous
studies implicating p38 in differentia-
tion control that were performed
mostly using mutant, overexpressed
forms of MAPK14 or its pathway
components. From these and other
studies, it is apparent that MAPK14
deficiency has broad-reaching effects
on proliferation of numerous cell types,
including lung epithelia, erythroblasts,
mouse embryonic fibroblasts, liver
cells, and cardiomyocytes (Ventura
et al., 2007; Hui et al., 2007; Engel
et al., 2005). Second, these two papers
demonstrate the antioncogenic activ-
ity of p38 and thus provide the first
genetic analyses of p38 function in
tumorigenesis in vivo. Both groups
point out that use of p38a as a possible
anti-inflammatory target may reap
unwanted consequences including
pulmonary failure or enhanced tumori-
genesis, important considerations for
future therapeutic approaches.
Whereas MAPK14 deficiency ap-
pears to have dramatic effects on dif-
ferentiation during development and
on lung tumorigenesis, the role of
MAPK14 in regulating lung stem or
progenitor cell function remains open
for interpretation. Most importantly, it
is not clear if Ventura et al. (2007)
analyzed lung epithelial stem cells.
The methods used for cell isolation
and culture differed substantially from
our initial characterization of BASCs.
The conditions used may have
selected for a different type of stem,
progenitor, or differentiated cell;
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or affected their gene expression com-
pared to the lung environment. More
precise analysis to rule out the possi-
bility of nonspecific lung cell marker
expression should be done, as well
as a functional analysis of individual,
freshly isolated cells. If MAPK14 is
required for lung tissue renewal as
proposed, Mapk14 mutant mice
should not be able to repair epithelial
cells after lung injury is invoked; such
experiments remain to be performed.
With the important implications for
lung stem cell biology raised by the
work of Ventura et al. (2007), and as
more studies of BASCs and/or other
lung stem/progenitor cells emerge, it
is crucial that the interpretations are
based on rigorous examination of
self-renewal and differentiation both
in vivo and in vitro. By combiningIs Ewing’s Sarco
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Solving the histogenesis of Ewin
standing its molecular pathogene
evidence supporting the hypoth
precursor.
One of the fundamental problems of
cancer research is the identification
of the progenitor cell that gives rise to
a clinically apparent tumor. For com-
mon epithelial cancers, such as breast
and colon cancers, the problem can
be narrowed to the cell types and
stages of differentiation that occur
within the target organ. Some cancers
that are anatomically more diverse,
such as melanoma, can be tracked
back to cells of a particular develop-
mental lineage, in that case to the neu-
ral crest. Pinning down the progenitor
cell in those diseases is tricky enough
but that seems simple compared toknowledge gained from these new
publications, important follow-up
work, and new distinct studies that
will emerge, it will become possible
for us to create a lineagemap that links
lung stem cells, progenitor cells, and
differentiated cells with the networks
that regulate their function.As the inter-
esting studies highlighted here show,
MAPK14 may help to map out a better
understanding of lung cell biology.
ACKNOWLEDGMENTS
The author thanks Juan Jose´ Ventura for clari-
fication of experimental approaches as well as
Genevieve Kruger, Nathan Young, and Sima
Zacharek for critical reading of the manuscript.
REFERENCES
Basseres, D.S., Levantini, E., Ji, H., Monti, S.,
Elf, S., Dayaram, T., Fenyus, M., Kocher, O.,ma a Stem Cell T
arch, National Cancer Institute, 37 Convent
g’s sarcoma has defied investiga
sis. In a recent issue of Cancer
esis that this rare cancer arises
the problem posed by a number of
rare cancers, mostly sarcomas, that
may occur in a variety of anatomic
sites and therefore do not necessarily
declare their origin by arising from
a particular tissue (Helman and Melt-
zer, 2003). One of the greatest puzzles
has been Ewing’s sarcoma, named
after the pathologist James Ewing
whose work helped to define this en-
tity. In a recent paper in Cancer Cell,
Delattre and colleagues place one
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et al., 2007).
Ewing’s sarcoma is a rare tumor that
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tors despite progress in under-
Cell, Tirode et al. (2007) present
from a primitive mesenchymal
adults. Despite progress in treating
this disease, it has a high propensity
to metastasize and remains lethal in
a substantial fraction of patients. Al-
though Ewing’s sarcoma frequently
appears to arise in bones, this is not
always the case, as there are clearly
extraosseous tumors. Moreover, it
does not typically express morpholog-
ical or biochemical markers sugges-
tive of bone differentiation. The tumors
are typically described as composed
of ‘‘small round blue cells’’ that may
express neural markers but do not
otherwise exhibit features that place
them clearly in any developmental
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